1. ALLA AKTIER
  2. NYHETER
  3. BBS-BIOACTIVE BONE SUBSTITUTES

BBS-Bioactive Bone Substitutes

Nyheter BBS-Bioactive Bone Substitutes Nyheter alla bolag

BBS-Bioactive Bone Substitutes Plc – Insider information: The results of change negotiations

MARKN.

BBS-Bioactive Bone Substitutes Plc | Company Release | December 13, 2024 at 09:30:00 EET

BBS-Bioactive Bone Substitutes Plc – Insider information: The results of change negotiations

The change negotiations started in the company on 22 November 2024 have ended. The negotiations covered the entire BBS-Bioactive Bone Substitutes Plc staff of 24 people.

The aim of the negotiations has been to achieve cost savings so that the company has as much time as possible to evaluate all possible alternative measures regarding the company's additional financing and strategic industrial cooperation options.

As a result of the change negotiations, the company will temporarily lay off 13 people full-time and 5 people part-time. In addition to the personnel savings mentioned above, the company aims to achieve additional savings from other operational costs of the business.

For more information, please contact:
Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

Distribution
Nasdaq Helsinki
https://www.bbs-artebone.fi/

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Attachments
BBS-Bioactive Bone Substitutes Plc – Insider information: The results of change negotiations

Datum 2024-12-13, kl 08:30
Källa MFN
Bifogade filer
BBS-Bioactive Bone Substitutes Plc – Insider information: The results of change negotiations
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!